Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
Nyxoah SA - Ordinary Shares (NYXH)
Company Research
Source: GlobeNewswire
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints Reports an Apnea-Hypopnea Index (AHI) responder rate of 63.5% on an intent to treat (ITT) basis (p=0.002)Reports an Oxygen Desaturation Index (ODI) responder rate of 71.3% on an intent to treat (ITT) basis (pMedian 12-month AHI reduction of 70.8% Mont-Saint-Guibert, Belgium – March 19, 2024, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis. The DREAM study is a pivotal trial, being conducted under an investigational device exemption (IDE) and is designed to support the marketing authorization of the Genio® hypoglos
Show less
Read more
Impact Snapshot
Event Time:
NYXH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NYXH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NYXH alerts
High impacting Nyxoah SA - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NYXH
News
- Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical OfficerGlobeNewswire
- Information on the total number of voting rights and sharesGlobeNewswire
- Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationGlobeNewswire
- Nyxoah S.A. (NASDAQ: NYXH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock, up previously from $18.00.MarketBeat
- Nyxoah S.A. (NASDAQ: NYXH) had its price target raised by analysts at Stifel Nicolaus from $20.00 to $27.00. They now have a "buy" rating on the stock.MarketBeat
NYXH
Earnings
- 3/5/24 - Miss
NYXH
Sec Filings
- 4/15/24 - Form 6-K
- 3/20/24 - Form 20-F
- 3/19/24 - Form 6-K
- NYXH's page on the SEC website